Site Editor

Rebecca Olin, MD, MS


David P. Steensma, MD, on Talking to Patients With AML About Taking Part in First-in-Human Trials

Posted: Sunday, March 1, 2020

David P. Steensma, MD, of Dana-Farber Cancer Institute, discusses how he approaches patients about entering a phase I trial, citing as an example his study of H3B-8800, a scientifically complex splicing modulator designed to treat acute myeloid leukemia and other hematologic malignancies.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.